Evidence map›Paper›PMID 27175020›Full record

ArticleG3 (Bethesda, Md.)2016

CRISPR/Cas9-Mediated Insertion of loxP Sites in the Mouse Dock7 Gene Provides an Effective Alternative to Use of Targeted Embryonic Stem Cells.

Kathleen A Bishop, Anne Harrington, Evguenia Kouranova, Edward J Weinstein, Clifford J Rosen, Xiaoxia Cui, Lucy Liaw

Open access · goldAbstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Deletion ofbioRxiv : the preprint server for biology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Kathleen A BishopCenter for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine 04074.
Anne HarringtonCenter for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine 04074.
Evguenia KouranovaHorizon Discovery, St. Louis, Missouri 63146.
Edward J WeinsteinHorizon Discovery, St. Louis, Missouri 63146.
Clifford J RosenCenter for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine 04074.
Xiaoxia CuiHorizon Discovery, St. Louis, Missouri 63146.
Lucy LiawCenter for Molecular Medicine, Maine Medical Center Research Institute, Scarborough, Maine 04074 liawl@mmc.org.
Maine Medical Center Research Institute · USHorizon Discovery Group (United States) · US

Funding

Phase III COBRE in Vascular BiologyP30GM103392 · NIGMS · MAINEHEALTH · PI ST. GERMAIN, DONALD L. · 2012 to 2016
$4.7M
Contribution of Notch Signaling to Vascular RemodelingR01HL070865 · NHLBI · MAINE MEDICAL CENTER · PI LIAW, LUCY · 2003 to 2017
$4.6M
Misty: a model for central regulation of bone remodelingR01AG040217 · NIA · MAINEHEALTH · PI ROSEN, CLIFFORD JAMES · 2011 to 2015
$1.7M
Mechanisms regulating Dock7-dependent osteoblast mobility and bone formationF32AR067071 · NIAMS · MAINEHEALTH · PI BECKER, KATHLEEN A · 2015 to 2017
$190k
NHLBI NIH HHS R01 HL070865NIAMS NIH HHS F32 AR067071NIA NIH HHS R01 AG040217NIGMS NIH HHS P30 GM103392
6 · The paper itself

Abstract

Targeted gene mutation in the mouse is a primary strategy to understand gene function and relation to phenotype. The Knockout Mouse Project (KOMP) had an initial goal to develop a public resource of mouse embryonic stem (ES) cell clones that carry null mutations in all genes. Indeed, many useful novel mouse models have been generated from publically accessible targeted mouse ES cell lines. However, there are limitations, including incorrect targeting or cassette structure, and difficulties with germline transmission of the allele from chimeric mice. In our experience, using a small sample of targeted ES cell clones, we were successful ∼50% of the time in generating germline transmission of a correctly targeted allele. With the advent of CRISPR/Cas9 as a mouse genome modification tool, we assessed the efficiency of creating a conditional targeted allele in one gene, dedicator of cytokinesis 7 (Dock7), for which we were unsuccessful in generating a null allele using a KOMP targeted ES cell clone. The strategy was to insert loxP sites to flank either exons 3 and 4, or exons 3 through 7. By coinjecting Cas9 mRNA, validated sgRNAs, and oligonucleotide donors into fertilized eggs from C57BL/6J mice, we obtained a variety of alleles, including mice homozygous for the null alleles mediated by nonhomologous end joining, alleles with one of the two desired loxP sites, and correctly targeted alleles with both loxP sites. We also found frequent mutations in the inserted loxP sequence, which is partly attributable to the heterogeneity in the original oligonucleotide preparation.

Indexed as

Clustered Regularly Interspaced Short Palindromic RepeatsCRISPR-Cas SystemsAllelesAnimalsBase SequenceDNA End-Joining RepairEmbryonic Stem CellsEndonucleasesExonsFemaleGene EditingGene TargetingGTPase-Activating ProteinsGuanine Nucleotide Exchange FactorsMiceMice, Inbred C57BLDock7 protein, mouseEndonucleasesGTPase-Activating ProteinsGuanine Nucleotide Exchange FactorsRNA, Guide, CRISPR-Cas SystemsCRISPR/Cas9Dock7KOMP ES cells

Identifiers

PMID27175020
PMCPMC4938658
OpenAlexW2409730325

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.